Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Andros Pharmaceuticals Co has a quick ratio of 13.91. It generally indicates good short-term financial strength.
The historical rank and industry rank for Andros Pharmaceuticals Co's Quick Ratio or its related term are showing as below:
ROCO:6917'
s Quick Ratio Range Over the Past 10 Years
Min: 4.21 Med: 13.57 Max: 14.13
Current: 13.91
During the past 7 years, Andros Pharmaceuticals Co's highest Quick Ratio was 14.13. The lowest was 4.21. And the median was 13.57.
ROCO:6917's Quick Ratio is ranked better than 85.75% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs ROCO:6917: 13.91
Andros Pharmaceuticals Co (ROCO:6917) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Andros Pharmaceuticals Co Quick Ratio Related Terms
Andros Pharmaceuticals Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Andros Pharmaceuticals Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co (ROCO:6917) has a Quick Ratio of 13.91 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Andros Pharmaceuticals Co and its competitors. This is near median its historical median of 13.57. Over the past decade, Andros Pharmaceuticals Co's Quick Ratio has ranged from 4.21 to 14.13. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #201 out of 1411 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Andros Pharmaceuticals Co's Quick Ratio too high?
Andros Pharmaceuticals Co's current Quick Ratio of 13.91 is near median its 10-year median of 13.57. Over the past 10 years, this metric has ranged from a low of 4.21 to a high of 14.13. The Biotechnology industry median Quick Ratio is 3.60. Andros Pharmaceuticals Co's value of 13.91 is 286.4% above this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #201 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #201 out of 1411 companies for Quick Ratio. This places Andros Pharmaceuticals Co in the top 14% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Andros Pharmaceuticals Co's value of 13.91 is 286.4% above this benchmark. Historically, Andros Pharmaceuticals Co's own Quick Ratio has ranged from 4.21 to 14.13 over the past decade. While the company's 10-year median is 13.57 vs. the industry median of 3.60, Andros Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current Quick Ratio of 13.91 is 286.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current Quick Ratio is 13.91, which is near median its own 10-year median of 13.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Quick Ratio is 13.91, which is near median its 10-year median of 13.57 and 286.4% above the Biotechnology industry median of 3.60. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Quick Ratio is 13.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
Quick Ratio: 13.91 (near median its 10-year median of 13.57)
GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
Industry Position: 286.4% above the Biotechnology median (#201 of 1411)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
